[1]
|
Turner, R.C., Cull, C.A., Frighi, V. and Holman, R.R. (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Journal of the American Medical Association (JAMA), 281, 2005-2012. doi:10.1001/jama.281.21.2005
|
[2]
|
Iltz, J.L., Baker, D.E., Setter, S.M. and Keith Campbell, R. (2006) Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics, 28, 652-665. doi:10.1016/j.clinthera.2006.05.006
|
[3]
|
Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. (2004) Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27, 2628-2635.
doi:10.2337/diacare.27.11.2628
|
[4]
|
DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092-1100.
doi:10.2337/diacare.28.5.1092
|
[5]
|
Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083-1091. doi:10.2337/diacare.28.5.1083
|
[6]
|
Norris, S.L., Lee, N., Thakurta, S. and Chan, B.K. (2009) Exenatide efficacy and safety: A systematic review. Diabetic Medicine, 26, 837-846.
doi:10.1111/j.1464-5491.2009.02790.x
|
[7]
|
Donekal S. and Shomali ME. (2008) Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. Diabetes Research and Clinical Practice, 80, e4-e6.
doi:10.1016/j.diabres.2008.01.014
|
[8]
|
Brixner, D.I., McAdam-Marx, C., Ye, X., Boye, K.S., Nielsen, L.L., Wintle, M., Misurski, D. and Fabunmi, R. (2009) Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism, 11, 1122-1130.
doi:10.1111/j.1463-1326.2009.01081.x
|
[9]
|
Buse, J.B., Klonoff, D.C., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., Maggs, D.G. and Wintle, M.E. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics, 29, 139-153. doi:10.1016/j.clinthera.2007.01.015
|